Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial

Fineline Cube Dec 22, 2025
Company Drug

Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis

Fineline Cube Dec 22, 2025
Company Deals

Ascletis Partners with Simcere for Ritonavir Supply in COVID-19 Drug Development

Fineline Cube Jan 17, 2023

China-based Ascletis Pharma Inc. (HKG: 1672) has announced that its wholly-owned subsidiary Ascletis Pharmaceuticals Co.,...

Company Drug

Simcere’s COVID-19 Drug SIM0417 Accepted for Special Review by NMPA

Fineline Cube Jan 17, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced that the National Medical Products Administration (NMPA)...

Company Drug

Bristol-Myers Squibb’s Opdivo Secures Two New Approvals for Esophageal Cancer in China

Fineline Cube Jan 17, 2023

US-based pharmaceutical giant Bristol-Myers Squibb (BMS, NYSE: BMY) has received two new indication approvals in...

Company Drug

Henlius’ PD-1 Inhibitor HanSiZhuang Approved for First-Line SCLC Indication

Fineline Cube Jan 17, 2023

Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) has announced receiving another indication approval from China’s...

Company Medical Device

Agilis Robotics Completes Successful Animal Testing for Surgical Robot

Fineline Cube Jan 17, 2023

Hong Kong-based Agilis Robotics Ltd has successfully completed a second round of live animal testing...

Company Deals

CARsgen and Huadong Medicine Partner to Commercialize BCMA CAR-T Product CT053 in China

Fineline Cube Jan 17, 2023

China-based CARsgen Therapeutics Holdings Limited (HKG: 2171), a leading developer of innovative CAR T-cell therapies,...

Company Deals

Tongshu Gene Partners with LC Gene to Distribute Gene Mutation Detection Kit in China

Fineline Cube Jan 17, 2023

China-based gene testing service providers Tongshu Gene and LC Gene Diagnostics (Hangzhou) Co., Ltd. have...

Company Drug

3D Medicines’ 3D185 Receives Orphan Drug Designation for Gastric Cancer

Fineline Cube Jan 16, 2023

China-based oncology specialist 3D Medicines (HKG: 1244) has announced receiving orphan drug designation (ODD) status...

Company Drug

Ascletis Pharma Initiates Dosing in Phase I Trial for COVID-19 Treatment ASC11

Fineline Cube Jan 16, 2023

China-based Ascletis Pharma Inc. (HKG: 1672) has announced the dosing of four healthy subjects in...

Company Deals

Base Therapeutics Secures Series A1 Funding to Advance Gene Editing Pipelines

Fineline Cube Jan 16, 2023

Base Therapeutics, a Guangdong-based firm specializing in base editing and prime editing technologies, has reportedly...

Company Deals

ConceMed Raises Pre-Series A Funding to Expand Digestive Endoscope Pipeline

Fineline Cube Jan 16, 2023

ConceMed, a Guangdong-based maker of digestive soft electronic endoscopes, has reportedly raised “tens of millions”...

Company Drug

Luye Pharma’s Rykindo Receives FDA Approval for Schizophrenia and Bipolar I Disorder

Fineline Cube Jan 16, 2023

China-based Luye Pharma Group (HKG: 2186) has announced receiving market approval from the US Food...

Company

WuXi Biologics CEO Outlines Growth Amid Global Challenges at J.P. Morgan Conference

Fineline Cube Jan 16, 2023

China-based WuXi Biologics (HKG: 2269) delivered a speech at the J.P. Morgan Healthcare Conference, where...

Company Drug

Hengrui’s Generic Cyclophosphamide Capsules Approved by China’s NMPA

Fineline Cube Jan 16, 2023

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving marketing approval from the National Medical...

Company Deals

ReLive Biotechnologies Acquires Co.Don AG, Secures USD 36 Million for Expansion

Fineline Cube Jan 16, 2023

Tissue engineering and regenerative medicine start-up ReLive Biotechnologies Ltd has announced the full acquisition of...

Company Drug

Akeso’s Penpulimab Secures New Approval for Lung Cancer Indication

Fineline Cube Jan 16, 2023

China-based Akeso Biopharma (HKG: 9926) has announced receiving another indication approval from the National Medical...

Company Drug

Clover Biopharmaceuticals Plans COVID-19 Vaccine SCB-2019 Launch in China for 2023

Fineline Cube Jan 16, 2023

China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has provided updates on its plans for the commercialization...

Company Drug

Amoytop’s AK0706 Receives Clinical Trial Approval for Hepatitis B Treatment

Fineline Cube Jan 16, 2023

Xiamen-based Amoytop Biotech Co. Ltd has announced receiving clinical trial approval from China’s National Medical...

Company Deals

JHM Biopharma Raises RMB100 Million to Expand Protein Drug Pipeline

Fineline Cube Jan 16, 2023

Hangzhou-based protein drug developer JHM Biopharma has reportedly secured close to RMB100 million (USD14.9 million)...

Company Drug

Sino Biopharma’s PD-L1 Combo with Anlotinib Accepted for Review by China’s CDE

Fineline Cube Jan 16, 2023

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its New Drug Application (NDA) filing...

Posts pagination

1 … 507 508 509 … 600

Recent updates

  • Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial
  • Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis
  • MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED
  • Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal
  • Merck’s Pimicotinib Wins China Approval as First Class 1 Therapy for TGCT
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial

Company Drug

Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis

Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.